Updated on 16 January 2015
Thermo Fisher Scientific has launched Oncomine Solid Tumor DNA kit
Singapore: Thermo Fisher Scientific has launched Oncomine Solid Tumor DNA kit for multiplexed sequencing of tumor samples at clinical laboratories.
According to the company, compared to other molecular diagnostic testing methods, such as qPCR or Sanger sequencing, next-generation sequencing (NGS) can assess a broader range of genes in a single test. Based on the Ion Torrent AmpliSeq technology, the kit allows detection of single nucleotide somatic changes, inversions, insertions.
The panel was verified by leading clinicians from the OncoNetwork Consortium with a focus on colon and lung cancer. Marked for in vitro diagnostic use in the European Union, the kit captures regions of human somatic variants (deletions, insertions, inversions, and substitutions) present in selected regions of cancer-related genes (EGFR, ALK, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, MET, DDR2, KRAS, PIK3CA, BRAF, AKT1, PTEN, NRAS, MAP2K1, STK11, NOTCH1, CTNNB1, SMAD4, FBXW7, TP53) for analysis using NGS technology.
"With this new CE-IVD Oncomine Solid Tumor DNA kit, we can enable the screening of the actionable mutations involved in colon and lung cancer with the high level performance that is required in a clinical laboratory setting," said Mr Nicola Normanno, chief of the laboratory Of pharmacogenomics at the Centro Ricerche Oncologiche in Mercogliano, Avellino, Italy.
"The release of the CE-IVD Oncomine Solid Tumour DNA kit is a major advance for clinical service provision in so far as it will dramatically reduce in house validation for accreditation purposes and will allow the implementation of accurate and reproducible screening of pertinent mutations in colon and lung cancers," said Professor Orla Sheils from Trinity College, Dublin.